We first confirmed that KPT-330 attenuated levels of XPO1 in two RCC cell lines at a similar magnitude (from 0.1 μM) to that which was observed with previously developed inhibitors of this nuclear transporter (Fig. 1A) [13]. This evidence concerns the gene RPAIN and renal cell carcinoma.